Genome occupancy profiling by high throughput sequencing ChIP-seq of Brd4 with or without Doxycycline treatment to induce Med12 or Med23 shRNAs in MLL-AF9 transformed acute myeloid leukemia cells (RN2
Human iPS cells (WT ASE9203 cells) were obtained from Applied Stem Cell (ASC), and CRISPR-Cas9-mediated gene editing was completed by ASC using their proprietary CRISPR-Cas9 protocol to introduce the
Enhancer activity and RUNX1 binding was studied using ChIP-seq in mixed lineage leukemia t(4;11) rearranged acute lymphoblastic leukemia upon inhibition of the WEE1 kinase. Overall design: ChIP-seq pr
The goals of this study are to identify ASXL2 binding sites in SKNO1 cells Examination of chromatin accessbility in AML1ETO9a leukemia with or without ASXL2